
Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine
Neurology® Podcast
00:00
The FDA Shouldn't Approve Aticanama Ut
The fda should not have approved aducana mab, and yet i will prescribe y mab, but reluctantly. I am one among those physicians who disagree with this decision. And so yes, if after someone learns all about this very complicated drug, and they fit the criteria for it, you know, i am a reluctant prescriber out of that respect for their individual autonomy.
Transcript
Play full episode